Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

@article{Iwamoto2011GenePA,
  title={Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.},
  author={T. Iwamoto and G. Bianchini and D. Booser and Y. Qi and C. Coutant and C. Shiang and L. Santarpia and J. Matsuoka and G. Hortobagyi and W. Symmans and F. Holmes and J. O’Shaughnessy and B. Hellerstedt and J. Pippen and F. Andr{\'e} and R. Simon and L. Pusztai},
  journal={Journal of the National Cancer Institute},
  year={2011},
  volume={103 3},
  pages={
          264-72
        }
}
BACKGROUND We hypothesized that distinct biological processes might be associated with prognosis and chemotherapy sensitivity in the different types of breast cancers. METHODS We performed gene set analyses with BRB-ArrayTools statistical software including 2331 functionally annotated gene sets (ie, lists of genes that correspond to a particular biological pathway or biochemical function) assembled from Ingenuity Pathway Analysis and Gene Ontology databases corresponding to almost all known… Expand

Paper Mentions

Interventional Clinical Trial
The aim of this project is to evaluate tailored primary systemic therapy with sequential nab paclitaxel and epirubicin and cyclophosphamide in early breast cancer. This study will be an… Expand
ConditionsBreast Cancer
InterventionDrug
Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer
TLDR
A systems biology network-based approach may facilitate the discovery of biomarkers for predicting chemotherapy responses in breast cancer and contribute in developing personalized medicines. Expand
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
TLDR
Different processes and pathways are associated with pCR in different BC subtypes. Expand
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
TLDR
ER-positive and ER-negative breast cancers have different biological pathways in BCBM development, and no BCBM-specific genes met the significance tests when the cancers were stratified by ER status. Expand
Identification of key genes as potential biomarkers for triple-negative breast cancer using integrating genomics analysis
TLDR
A number of key genes are identified as potential biomarkers involved in TNBC, which provide novel insights into the tumorigenesis of TNBC at the gene level and may serve as independent prognostic factors for TNBC prognosis. Expand
Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
TLDR
Major transcriptomic changes induced by NAC are revealed and suggest that chemotherapy-induced gene expression changes observed early in therapy may be good predictors of response to NAC. Expand
Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer
TLDR
The number of biological pathways, and therefore genes, that are associated with prognosis or treatment sensitivity are substantially larger and more consistent in ER+ cancers than among ER- tumors, which implies that it is easier to discover prognostic and predictive markers for ER+ than for ER- cancers. Expand
Integrative analysis of survival-associated gene sets in breast cancer
TLDR
The GSAS metric provided a useful medium by which it was used to identify predictive gene sets and to construct a novel gene set containing genes heavily involved in cancer progression. Expand
Genomic Applications in Breast Carcinoma
TLDR
Sequencing-based assays will soon be incorporated into the diagnostic armamentarium of pathologists for the optimal selection of systemic therapies for breast cancer patients, with the advent of massively parallel sequencing and the ability to characterize cancer genomes at base pair resolution, driver genes and actionable mutations have been identified. Expand
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
TLDR
The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not. Expand
Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17
TLDR
Non-HER2 chr17 CN patterns may further predict outcome in breast cancer patients with known favorable and unfavorable prognosis, and TOP2A FISH and qPCR may not identify the same pathology on chr 17q. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
TLDR
It is shown that divergent gene sets classifying patients for the same clinical endpoint represent similar biological processes and that pathway-derived signatures can be used to predict prognosis and that the underlying biology related to aggressiveness of estrogen receptor subgroups of breast cancer is quite different. Expand
Evaluation of biological pathways involved in chemotherapy response in breast cancer
TLDR
Genes involved in the E2F3 pathway are associated with chemotherapy sensitivity among ER-negative cancers and the mutant p53-signature and expression of ER-related genes were associated with lower sensitivity to chemotherapy in ER-positive breast cancers only. Expand
The humoral immune system has a key prognostic impact in node-negative breast cancer.
TLDR
It is shown in three cohorts of untreated, node-negative breast cancer patients that the humoral immune system plays a pivotal role in metastasis-free survival of carcinomas of the breast. Expand
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
TLDR
The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options. Expand
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
TLDR
The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers. Expand
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
  • G. Bianchini, Y. Qi, +13 authors L. Pusztai
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
Among ER-negative and ER-positive highly proliferative cancers, a subset of tumors with high expression of a B-cell/plasma cell metagene carries a favorable prognosis, and different thresholds apply in the two subgroups. Expand
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
TLDR
Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups. Expand
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
TLDR
The results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype. Expand
Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
TLDR
P53 dysfunction is prognostically most relevant in ER+ cancers and supports the hypothesis that different predictive or prognostic markers will be needed for different molecular subsets of breast cancer. Expand
Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer
TLDR
This study suggests that high tau mRNA expression in ER-positive breast cancer indicates an endocrine-sensitive but chemotherapy-resistant disease, and low tau expression identifies a subset of ER- positive cancers that have poor prognosis with tamoxifen alone and may benefit from taxane-containing chemotherapy. Expand
...
1
2
3
4
...